insitro and Lilly Forge Partnerships to Advance AI-Powered siRNA Drugs for Metabolic Diseases
Insitro, a leading AI-driven drug discovery and development company, has entered into three strategic agreements with Eli Lilly and Company
Read moreInsitro, a leading AI-driven drug discovery and development company, has entered into three strategic agreements with Eli Lilly and Company
Read moreAI firm Generate:Biomedicines announced on Tuesday that it has secured a $1B+ collaboration with Novartis to advance AI-driven protein therapeutics.
Read moreGoogle DeepMind has introduced AlphaProteo, an advanced AI system designed to generate novel proteins that bind to specific molecular targets.
Read moreIn a forward-thinking move, Sanofi, Formation Bio, and OpenAI have joined forces to harness the power of artificial intelligence in
Read moreThe AI-driven image analysis software, MMI CellDetector, is designed to automatically identify and quantify cellular phenotypes across a wide range
Read moreIn a proof-of-concept study, researchers at the National Institutes of Health (NIH) explored the feasibility of employing transfer learning, a machine
Read moreAmerican biotechnology corporation Genentech, a key player in research and early drug development and a subsidiary of the Roche Group,
Read moreMcMaster University and the Massachusetts Institute of Technology researchers using artificial intelligence (AI) have discovered a new type of antibiotic
Read moreMachine learning tissue classifiers are one of the most powerful and promising AI-based clinical research solutions for all types of
Read moreFrench pharma giant Sanofi and British pharmatech business Exscientia revealed a ground-breaking research cooperation and licensing agreement to develop up
Read more